SCHEMBL15973709

SCHEMBL15973709

COc1ccc(CN2C(=O)NC(CCc3ccccc3)C2=O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.62
KMT2A Q03164 2/20 0.61
MEN1 O00255 1/20 0.61
LMNA P02545 3/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.57
POLB P06746 3/20 0.52
MMP1 P03956 1/20 0.51
MMP3 P08254 1/20 0.51
MMP9 P14780 1/20 0.51
HTT P42858 1/20 0.51
GAA P10253 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
TSHR P16473 1/20 0.50
PIM1 P11309 2/20 0.49
CMA1 P23946 1/20 0.49
HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13793062 0.93 ALDH1A1 (0.54) ALDH1A1KMT2AMEN1LMNASMN1; SMN2
SCHEMBL13879503 0.88 ALDH1A1 (0.77) ALDH1A1KMT2AMEN1LMNASMN1; SMN2
SCHEMBL3996653 0.83 CMA1 (0.47) ALDH1A1KMT2AMEN1LMNASMN1; SMN2
SCHEMBL13793057 0.83 ALDH1A1 (0.51) ALDH1A1KMT2AMEN1LMNASMN1; SMN2
SCHEMBL13793064 0.83 CMA1 (0.47) ALDH1A1KMT2AMEN1LMNASMN1; SMN2
SCHEMBL13792818 0.82 TP53 (0.53) ALDH1A1KMT2AMEN1LMNAL3MBTL1
SCHEMBL13792199 0.82 CMA1 (0.46) ALDH1A1KMT2AMEN1LMNASMN1; SMN2
SCHEMBL13792124 0.82 L3MBTL1 (0.46) ALDH1A1KMT2AMEN1L3MBTL1POLB
SCHEMBL14686682 0.81 CMA1 (0.57) ALDH1A1KMT2AMEN1L3MBTL1MMP1
SCHEMBL13879473 0.81 NR1H3 (0.51) ALDH1A1KMT2AMEN1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11028052-B2 Compounds useful as modulators of TRPM8 FIRMENICH INCORPORATED (US) 2021-06-08 US disclosed
EP-3461816-B1 FIVE-MEMBERED HETEROCYLIC COMPOUNDS USEFUL AS MODULATORS OF TRPM8 FIRMENICH INCORPORATED (US) 2021-03-24 EP disclosed
US-10421727-B2 Compounds useful as modulators of TRPM8 FIRMENICH INCORPORATED (US) 2019-09-24 US disclosed
EP-3461816-A1 FIVE-MEMBERED HETEROCYLIC COMPOUNDS USEFUL AS MODULATORS OF TRPM8 Senomyx, Inc. (US) 2019-04-03 EP disclosed
US-20170369447-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 FIRMENICH INCORPORATED 2017-12-28 US disclosed
US-9840471-B2 Compounds useful as modulators of TRPM8 SENOMYX, INC. (US) 2017-12-12 US disclosed
US-20150376136-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 SENOMYX, INC. 2015-12-31 US disclosed
EP-2958897-A2 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 Senomyx, Inc. (US) 2015-12-30 EP disclosed
WO-2014130582-A2 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 SENOMYX, INC. (US) 2014-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10421727-B2 Compounds useful as modulators of TRPM8 TRPM8, TRPM7, TRPA1 ALDH1A1 1692/4885KMT2A 2891/4885MEN1 649/4885
US-20150376136-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 TRPM8, TRPM7, TRPA1 ALDH1A1 1692/4885KMT2A 2891/4885MEN1 649/4885
US-20170369447-A1 COMPOUNDS USEFUL AS MODULATORS OF TRPM8 TRPM8, TRPM7, TRPA1 ALDH1A1 1692/4885KMT2A 2891/4885MEN1 649/4885
US-11028052-B2 Compounds useful as modulators of TRPM8 TRPM8, TRPM7, TRPA1 ALDH1A1 1692/4885KMT2A 2891/4885MEN1 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.